Atara Biotherapeutics, Inc.
atarabio.comWhat Do They Do?
Develops T-cell immunotherapies for patients with cancer and autoimmune diseases, including tab-cel for a transplant-related cancer.
10-K for FY2025, filed Mar 16, 2026Atara Biotherapeutics is a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to…View ↗
Tab-cel® (Ebvallo™) is an allogeneic EBV-specific T-cell immunotherapy that is approved in the EU and UK and currently in Phase 3…View ↗
Since its discovery as the first human oncovirus, EBV has been implicated in the development of a wide range of diseases, including…View ↗
How Do They Make Money?
Atara receives upfront fees, payments when regulatory or commercial milestones are met, royalties tied to product sales, and reimbursements as it performs transition services for Pierre Fabre.
10-K for FY2025, filed Mar 16, 2026As discussed in further detail in Note 5 - "Financial Instruments", the terms of our customer contracts include potential payments to us…View ↗
Milestone payments: At the inception of each arrangement that includes development milestone payments, we evaluate the probability of…View ↗
Royalties: For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is…View ↗
Transition plan cost reimbursements: Reimbursements for certain development, safety, regulatory and manufacturing services are recorded as…View ↗
Under the terms of the A&R Commercialization Agreement, as amended by the A&R Commercialization Agreement Amendment, we are entitled to…View ↗
$120.8M
-
10-K for FY2025, filed Mar 16, 2026
$120.8M ↗
Who Are Their Customers?
Atara's commercial relationship for tab-cel is with Pierre Fabre under an exclusive worldwide license; Pierre Fabre handles its development, manufacturing, commercialization and distribution.
10-K for FY2025, filed Mar 16, 2026On October 31, 2023, we entered into the A&R Commercialization Agreement, which became effective in December 2023 (A&R Commercialization…View ↗
In March 2025, we completed the transfer of all manufacturing responsibility to Pierre Fabre under the A&R Commercialization Agreement…View ↗
In May 2025, we aligned with the FDA on a plan to address the issues raised by the FDA in the Response Letter and the path forward for…View ↗
In October 2025, we further amended the A&R Commercialization Agreement to transfer all regulatory activities (including sponsorship of the…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 27 cents of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$50.9M.
10-K for FY2025, filed Mar 16, 2026
$35.9MView ↗
10-K for FY2025, filed Mar 16, 2026
$32.7MView ↗
10-K for FY2025, filed Mar 16, 2026
−$50.9MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$4.8MView ↗
- ▼ Now a loss
- vs $2.4M in Q2 FY2025
-
Aug 12, 2026
FDA meeting provides a path to resubmit the tab-cel application
Pierre Fabre plans to submit updated trial data with additional patients and longer follow-up.
Sources
8-K, filed Aug 12, 2026
“This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a productive Type A meeting with the…View ↗
-
Jun 26, 2026
Atara appoints an interim chief financial officer
Sources
8-K, filed Jun 26, 2026
On June 26, 2026, the Company’s Board of Directors appointed Kevin G. Sarney, Life Science Practice Leader at Charles River CFO, Inc.…View ↗
-
May 1, 2026
Nasdaq gives Atara time to meet its listing market-value requirement
Atara's stock continued trading while the company had time to meet the requirement; failure to do so could lead to delisting.
Sources
8-K, filed May 1, 2026
On April 30, 2026, Atara Biotherapeutics, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department…View ↗
Programs discontinued
The earlier report described an active multiple-sclerosis program and several CAR T programs; the newer report says multiple-sclerosis development stopped and CAR T operations were discontinued, while rights to the multiple-sclerosis and EBV vaccine programs returned to QIMR.
10-K for FY2022, filed Feb 8, 2023 10-K for FY2025, filed Mar 16, 2026ATA188: T-cell immunotherapy targeting EBV antigens, believed to be important for the potential treatment of primary and secondary…View ↗
ATA3219: Allogeneic CAR T targeting CD19, currently in preclinical development, and being developed as a potential best-in-class product…View ↗
In addition to the aforementioned strategic priorities, we also have a number of clinical and preclinical programs, including ATA2271, an…View ↗
Wider tab-cel rights
The partnership moved from selected regions to worldwide rights for tab-cel, with Pierre Fabre taking on manufacturing, clinical-development and regulatory work.
10-K for FY2022, filed Feb 8, 2023 10-K for FY2025, filed Mar 16, 2026In October 2021, we entered into the Commercialization Agreement with Pierre Fabre (Pierre Fabre Commercialization Agreement), pursuant to…View ↗
On October 31, 2023, we entered into the A&R Commercialization Agreement, which became effective in December 2023 (A&R Commercialization…View ↗
In March 2025, we completed the transfer of all manufacturing responsibility to Pierre Fabre under the A&R Commercialization Agreement…View ↗
In May 2025, we aligned with the FDA on a plan to address the issues raised by the FDA in the Response Letter and the path forward for…View ↗
In October 2025, we further amended the A&R Commercialization Agreement to transfer all regulatory activities (including sponsorship of the…View ↗
Loading...
